Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Ambrisentan is a propanoic acid-based, A-selective endothelin receptor antagonist for the once-daily treatment of pulmonary arterial hypertension.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Circulation

Title: Circulation

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1524-4539

ISSN (Print): 0009-7322

Publication date (Electronic): Jun 10 2008

Volume: 117

Issue: 23

Affiliations

[1 ] Institute of Cardiology, University of Bologna, Via Massarenti, 9, 40138-Bologna, Italy. nazzareno.galie@unibo.it

Article

Publisher Item ID: CIRCULATIONAHA.107.742510

DOI: 10.1161/CIRCULATIONAHA.107.742510

PubMed ID: 18506008

SO-VID: bc454c07-5ff1-42dc-8a08-9d1a3d9ceeca

History

Data availability:

Comments

Comment on this article

scite_

Cited by 229

See all cited by

- Version 1